European Federation of Pharmaceutical Industries and Associations
EU lobbying footprint — who they meet, and on what. Built only from official disclosures, every meeting cited.
European Federation of Pharmaceutical Industries and Associations has 153 disclosed EU lobbying meetings from 2024-07-16 to 2026-06-11: 66 with the European Commission and 87 with Members of the European Parliament. Source: EU Transparency Register no. 38526121292-88, Commission disclosures and MEP declarations.
Lobbying profile
as declared 2025-12-17- Category
- Trade and business associations
- Legal status
- Non-profit association
- Declared lobbying cost
- €6,000,000
- Lobbying FTEs
- 13.4
- Members
- 12
Files it’s lobbying on
The org's disclosed policy areas, ranked by number of meetings.
Declared fields of interest
Budget · Business and industry · Climate action · Competition · Consumers · Customs · Digital economy and society · Employment and social affairs · Environment · External relations · Humanitarian aid and civil protection · Institutional affairs
At a glance
The officials and MEPs most often met, by disclosed-meeting count.
- Olivér Várhelyi8
- Jana Dabbelt3
- Maya Matthews3
- Marc Lemaitre2
- Carmen Laplaza Santos2
Disclosed meetings
Newest first, showing the most recent 60 of 153. EC = European Commission, EP = Member of the European Parliament.
- UWWTDsource ↗
- Health Policysource ↗
- 2026-05-22ECPatrick Child · Deputy Director-GeneralExtended Producer Responsibility under the recast Urban Wastewater Treatment Directivesource ↗
- Digital Omnibussource ↗
- Hosting the Conference "Promoting Early Detection for Better Cardiovascular Outcomes: Towards Comprehensive Health Check Programmes Across Europe"source ↗
- 2026-05-04ECMartin Seychell · Deputy Director-GeneralExchange of views on the EU global health approach, local manufacturing agenda and role of the EU pharmaceutical industry.source ↗
- Biotech Act expert briefing sessionsource ↗
- Cardiovascular Health Policy and Innovation in the EUsource ↗
- Schorzenia sercowo naczyniowe w UEsource ↗
- 2026-04-21ECLaszlo Kristoffy · Cabinet of Commissioner Olivér VárhelyiCurrent pharma affairssource ↗
- 2026-04-16ECJana Dabbelt · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- Biotech Actsource ↗
- Biotech Actsource ↗
- Urban Waste Water Directive - Resolutionsource ↗
- Digital Omnibussource ↗
- EU Health Policysource ↗
- 2026-03-26ECNils Behrndt · Deputy Secretary-GeneralCurrent context of pharmaceutical production in the EU and major challengessource ↗
- Biotech actsource ↗
- 2026-03-25ECEstelle Goeger · Cabinet of Executive Vice-President Stéphane SéjournéInternational context of the pharmaceutical industrysource ↗
- Biotech Act Isource ↗
- Biotech Actsource ↗
- Politischer Austauschsource ↗
- 2026-03-19ECMarc Lemaitre · Director-GeneralNext generation of European public-private partnerships under FP10 / Horizon Europesource ↗
- MDR/IVDRsource ↗
- EBCP reportsource ↗
- Health Policysource ↗
- 2026-02-25ECMarco Chirullo · Head of UnitExchange of views on EU cooperation with China and Japan in the field of biopharmaceutical innovation and supply chain resilience.source ↗
- 2026-02-25ECLucian Cernat · Head of UnitMutual Recognition Agreements (MRAs) for pharmaceutical products with reference to the UK and Türkiyesource ↗
- EU-US tradesource ↗
- 2026-02-17ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiBiotech Act, Pharma package, CMAsource ↗
- Exchange on the cardiovascular strategysource ↗
- 2026-02-11ECJana Dabbelt · Cabinet of Commissioner Olivér VárhelyiEnvironmental legislationsource ↗
- 2026-02-11ECMaya Matthews · Head of UnitExchange of views on operations under the HTA Regulation with a focus on joint clinical assessments (JCAs)source ↗
- EU Industry Policysource ↗
- Exchange of viewssource ↗
- Health policysource ↗
- 2026-01-21ECEric Mamer · Director-GeneralGeneral discussion on DG ENV prioritiessource ↗
- Cardio vascular deseases strategysource ↗
- Introductory Meetingsource ↗
- 2026-01-15ECCarmen Laplaza Santos · Head of UnitExchange of views with private members of the Innovative Health Initiative Joint Undertaking (IHI-JU).source ↗
- 2026-01-15ECMaria Pilar Aguar Fernandez · DirectorExchange of views with private members of the Innovative Health Initiative Joint Undertaking (IHI-JU).source ↗
- cardiovascular healthsource ↗
- 2025-12-11ECCarmen Laplaza Santos · Head of UnitAssessment of micropollutants in wastewatersource ↗
- 2025-12-03ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiFuture of European pharmaceuticals sectorsource ↗
- 2025-12-02ECEkaterina Zaharieva · Cabinet of Commissioner Ekaterina ZaharievaLife sciencessource ↗
- Pharma Packagesource ↗
- Pharmaceutical legislationsource ↗
- Review of the EU General Pharmaceutical Legislationsource ↗
- Exchange of viewssource ↗
- EU-US relationsource ↗
- EU Pharmaceutical Policysource ↗
- Critical Medicines Actsource ↗
- Cardiovascular Healthsource ↗
- CMAsource ↗
- 2025-11-04ECKilian Gross · Head of UnitExchange of views on the AI Act and how it applies to research and development activitiessource ↗
- 2025-10-28ECDorota Denning · Cabinet of Commissioner Valdis DombrovskisRoundtable on Simplification for Pharmaceutical Innovationsource ↗
- CMA & Biotech Actsource ↗
- EU pharmaceutical policiessource ↗
- 2025-10-22ECMaya Matthews · Head of UnitExchange of views on joint clinical assessment and joint scientific consultations under the HTA Regulation.source ↗
- Discussion on the Critical Medicines Actsource ↗
Frequently asked
How many EU lobbying meetings has European Federation of Pharmaceutical Industries and Associations disclosed?
European Federation of Pharmaceutical Industries and Associations (EU Transparency Register no. 38526121292-88) appears in 153 disclosed meetings with EU officials and MEPs between 2024-07-16 and 2026-06-11: 66 with the European Commission and 87 with Members of the European Parliament.
What does European Federation of Pharmaceutical Industries and Associations lobby on?
European Federation of Pharmaceutical Industries and Associations's disclosed EU meetings most often concern Health, Technology, Trade, Industry. Every meeting and its topic is listed with its official source on this page.
Who does European Federation of Pharmaceutical Industries and Associations meet in Brussels?
Across its disclosed meetings, European Federation of Pharmaceutical Industries and Associations has met Commission officials including Olivér Várhelyi, Jana Dabbelt, Maya Matthews, and MEPs including JARUBAS Adam, WÖLKEN Tiemo, ANDRIUKAITIS Vytenis Povilas. These are counts of officially disclosed meetings, not a measure of influence.
Primary sources
Every meeting above is a public disclosure by the European Commission or a Member of the European Parliament; counts are of disclosed meetings only and are not a measure of influence. Methodology. Data © European Union (Decision 2011/833/EU) & the European Parliament.
Related on the graph
The same footprint, mapped onto the topics and files it touches.
Get the EU lobbying brief
We’ll email you when major new lobbying meetings are disclosed — free, no account, built from public EU data with every entry cited. We only email on real updates.
See your company’s overlap with European Federation of Pharmaceutical Industries and Associations — and the rest of the corpus.
Enter your company and Lex builds a cited Exposure Map in about 30 seconds. Free, no login.